The trial showed that WM patients treated with Imbruvica experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of
If approved, lifitegrast has the potential to be the first treatment indicated to address both signs and symptoms of the disease. Lifitegrast is a new small-molecule integrin inhibitor
Relamorelin is Rhythm’s Phase II ghrelin agonist being developed for the treatment of diabetic gastroparesis and gastrointestinal (GI) functional disorders. Ghrelin is a peptide hormone produced in the
TCON is focused on the development and commercialization of new targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The agreement strengthens intellectual property estate around TRC102
The company intends to begin a Phase I trial in the second quarter of 2015 to evaluate the safety and tolerability of AGT-181 in adult patients with mucopolysaccharidosis
The FDA concluded that Perrigo’s products are therapeutically equivalent to Mallinckrodt’s Exalgo (hydromorphone HCI extended-release tablets) 8mg, 12mg and 16mg. According to the agency these products can be
CAP-1002 is being developed to treat advanced heart failure, including patients who were Class III or ambulatory Class IV with ejection fractions of 35% or below. A total
These standard chemotherapies include paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy. The approval was based on data from the pivotal
As part of the non-binding proposal, Perrigo shareholders would receive $205 in a combination of cash and Mylan stock for each Perrigo share. In a statement, Perrigo has
Designed to evaluate the safety and efficacy of ALX-0061, the trial is also aimed at obtaining parallel descriptive information concerning the efficacy and safety of administration of sc
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.